We represented a global healthcare company regarding a drug diversion allegation that controlled substances were inappropriately ordered, secured and dispensed by the company in violation of state and federal law. After conducting an internal investigation into the allegations and meeting with the DEA, the government declined to pursue further action against our client.
Global Healthcare Company Faces Drug Diversion Allegations
You Also May Be Interested In:
Successful Defense of National Home Healthcare Provider in Appealing $18 Million Extrapolated Overpayment Resulting from UPIC Audit
We successfully defended a national home healthcare provider in appealing an $18 million extrapolated overpayment resulting from a UPIC audit.
We represented a global for-profit health insurance company with more than 20 million members in False Claims Act (FCA) litigation in federal court in the Northern District of Illinois.
Representation of ED company and other defendants in qui tam lawsuit alleging that ED provider’s violation of licensure laws caused submission of false claims and that defendants fraudulently billed services as performed by physicians even though patients were seen only by nurse practitioners. We obtained dismissal of the licensure claims and received summary judgment as to the upcoding claims. U.S. ex rel. Taylor v. Boyko, 2020 WL 520933 (S.D. W. Va. Jan. 31, 2020); U.S. ex rel. Taylor v. Perni, 2020 WL 2499544 (S.D. W. Va. May 14, 2020).